Article Text

Download PDFPDF

Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
  1. Cora N Sternberg
  1. Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy
  1. Correspondence to Dr Cora N Sternberg, MD, FACP; cnsternberg{at}corasternberg.com

Statistics from Altmetric.com

Find the ESMO Clinical Practice Guidelines on Prostate Cancer here: http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate

The widespread use of prostatic specific antigen (PSA) testing has greatly impacted on the epidemiology of prostate cancer. Patients are often discovered at an early stage and testing is also performed in patients who are too elderly or frail for local treatments such as prostatectomy or radiation therapy. Only recently has there been an increased uptake in the use of active surveillance for selected patients with localised prostate cancer.1

Androgen deprivation therapy (ADT) has traditionally been reserved for patients with metastatic disease or in combination with radiation therapy for locally advanced disease.

The subject of when and how and to whom ADT should be given in patients with non-metastatic prostate cancer is highly controversial and filled with mystery, beliefs and differing practice …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles